
Eli Lilly stock drops 8.4% but Citi predicts 45% gain on strong obesity drug sales and pipeline.
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...





